Watch MMED. Know when insiders buy.
One email the day a filing lands. Free.
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jul 31 | $843M | +16.6% | 55.2% | $5M | $0 | — | 0.00 | −$49M | $41M | −$90M | Sep 8 |
| Q1 2026 · Apr 24derived | $837M | +15.6% | 57.3% | −$93M | −$185M | — | -0.71 | −$170M | $56M | −$226M | Jun 29 |
| Q 2026 · Jan 23 | $790M | +15.0% | 45.8% | −$100M | −$119M | — | -0.47 | — | — | — | Apr 17 |
| Q3 2025 · Oct 24 | — | — | — | — | −$5M | — | — | — | — | — | Apr 17 |
| Q2 2025 · Jul 25 | $723M | — | 56.6% | −$13M | −$19M | — | -0.08 | −$141M | $53M | −$194M | Sep 8 |
| Q1 2025 · Apr 25derived | $724M | — | 55.9% | −$148M | −$172M | — | -0.68 | $83M | $57M | $26M | Jun 29 |
| Q 2025 · Jan 24 | $687M | — | 57.5% | $21M | −$10M | — | -0.04 | — | — | — | Apr 17 |
| Q3 2024 · Oct 25 | — | — | — | — | −$5M | — | — | — | — | — | Apr 17 |
| Q2 2024 · Jul 26 | — | — | — | — | −$19M | — | — | — | — | — | Apr 17 |
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2026 · to Apr 24 | $3.1B | 54.2% | −$190M | −$333M | -10.7% | -1.30 | −$197M | $223M | −$420M | — | — |
| FY2025 · to Apr 25 | $2.7B | 56.3% | −$146M | −$213M | -7.8% | -0.84 | $140M | $193M | −$53M | — | — |
| FY2024 · to Apr 26 | $2.5B | 58.2% | −$69M | −$112M | -4.5% | -0.44 | $41M | $148M | −$107M | — | — |
Every number comes from MiniMed Group, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.